Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Aromatase

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    185 result(s) found for: Aromatase. Displaying page 1 of 10.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2013-001064-27 Sponsor Protocol Number: s55283 Start Date*: 2013-06-25
    Sponsor Name:University Hospitals Leuven
    Full Title: Placebo-controlled trial with vitamin D to prevent worsening/relieve aromatase inhibitor-induced musculoskeletal symptoms in breast cancer patients
    Medical condition: aromatase inhibitor-induced musculoskeletal symptoms in postmenopausal breast cancer patients
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: BE (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-001234-34 Sponsor Protocol Number: 118 Start Date*: 2020-04-08
    Sponsor Name:HUS Syöpäkeskus
    Full Title: Effects of Vaginal Estrogens on Serum Estradiol Levels in Postmenopausal Women with Breast Cancer Taking an Aromatase Inhibitor.
    Medical condition: Breast cancer, postmenopausal atrophic vaginitis
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004872 10036398 Postmenopausal atrophic vaginitis LLT
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Elderly Gender: Female
    Trial protocol: FI (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-002157-64 Sponsor Protocol Number: Start Date*: 2012-03-07
    Sponsor Name:Common Services Agency
    Full Title: ARomatase Inhibition plus minus SaracaTinib as Advanced breast CAncer Therapy: a randomised phase II study of aromatase inhibition plus/minus the src-inhibitor AZD0530 in post-menopausal women with...
    Medical condition: Advanced breast cancer
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2017-001022-17 Sponsor Protocol Number: 170304 Start Date*: 2017-05-08
    Sponsor Name:Breastcentre, Capio St Gorans Hospital
    Full Title: Vitamin D supplementation to breast cancer patients with adjuvant endocrine treatment – An observational clinical study where the patient is its own control.
    Medical condition: Breast cancer survivors on adjuvant treatment with an aromatase inhibitor having joint pain
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: SE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2008-004874-42 Sponsor Protocol Number: TRAFO001 Start Date*: 2009-02-06
    Sponsor Name:Institut für Frauengesundheit GmbH
    Full Title: Evaluation of predictive Factors for the Effectivity of Aromatase Inhibitor Therapy - Offene, prospektive, multizentrische Phase IV-Studie zur Untersuchung des Einflusses von pharmakogenetischen M...
    Medical condition: The study examines the influence of pharmacogenetic markers on the efficacy and side effects in postmenopausal, steroid hormone positive breast cancer patients, who are treated with Letrozol. The p...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10006187 Breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-005680-25 Sponsor Protocol Number: C/22/2011 Start Date*: 2012-04-24
    Sponsor Name:Imperial College London
    Full Title: A Phase II study to assess the safety and efficacy of the steroid sulfatase inhibitor Irosustat when added to an aromatase inhibitor in ER positive locally advanced or metastatic breast cancer pati...
    Medical condition: Locally advanced or metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10070577 Oestrogen receptor positive breast cancer PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-003185-25 Sponsor Protocol Number: GO29058 Start Date*: 2015-03-03
    Sponsor Name:F. Hoffmann-La Roche Ltd
    Full Title: A PHASE III, DOUBLE-BLIND, PLACEBO CONTROLLED, RANDOMIZED STUDY OF TASELISIB PLUS FULVESTRANT VERSUS PLACEBO PLUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ESTROGEN RECEPTOR POSITIVE AND HER2 NEGATI...
    Medical condition: WOMEN WITH ER-POSITIVE AND HER2-NEGATIVE, LOCALLY ADVANCED OR METASTATIC BREAST CANCER WHO HAS DIDEASE RECURRENCE OR PROGRESSION DURING OR AFTER AROMATASE INHIBITOR THERAPY
    Disease: Version SOC Term Classification Code Term Level
    17.1 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing) PT (Completed) ES (Completed) CZ (Completed) DE (Completed) AT (Completed) NL (Completed) PL (Completed) BG (Completed) FR (Completed) SE (Completed) GR (Completed) RO (Ongoing) FI (Completed)
    Trial results: View results
    EudraCT Number: 2005-003104-11 Sponsor Protocol Number: 1.0 Start Date*: 2005-10-11
    Sponsor Name:Fertility clinic Odense University Hospital
    Full Title: Androgen priming in the late luteal phase as a mean to improve the outcome of ovarian stimulation for IVF in normogonadotrophic women with a previously proven poor response
    Medical condition: Hypothesis. By combining pituitary downregulation with aromatase inhibitor, and hCG injection during a late luteal phase a powerful stimulation of thecal androgen production is achieved. Thereby, i...
    Disease:
    Population Age: Adults Gender: Female
    Trial protocol: DK (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-002964-22 Sponsor Protocol Number: AGO/2013/009 Start Date*: 2013-12-10
    Sponsor Name:Ghent University Hospital
    Full Title: Influence of aromatase inhibitors on insulin sensitivity, liver and hart function in obese men
    Medical condition: Influence of aromatase inhibitors on insulin sensitivity, liver and hart function in obese men
    Disease:
    Population Age: Adults Gender: Male
    Trial protocol: BE (Completed)
    Trial results: View results
    EudraCT Number: 2021-002217-34 Sponsor Protocol Number: FITO-01/21 Start Date*: 2022-07-26
    Sponsor Name:AZIENDA OSPEDALIERO-UNIVERSITARIA CAREGGI
    Full Title: Tuscany project to investigate on efficacy and safety of Cannabis phytotherapic preparations for the treatment of Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents: a pro...
    Medical condition: Aromatase iNhibitor-induced chronic resistaNt pAin in Breast cancer patIents
    Disease: Version SOC Term Classification Code Term Level
    20.0 10029205 - Nervous system disorders 10029205 Nervous system disorders SOC
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2020-005343-23 Sponsor Protocol Number: ADAIDO Start Date*: 2021-05-28
    Sponsor Name:IRCCS ISTITUTO ORTOPEDICO GALEAZZI S.P.A
    Full Title: Effect of the antiresorptive treatment with alendronate versus no treatment after denosumab and aromatase inhibitors discontinuation in low fracture risk osteopenic postmenopausal women with non me...
    Medical condition: post-menopausal osteoporosis in women with non-metastatic hormonal receptor positive (HR+) breast cancer.
    Disease: Version SOC Term Classification Code Term Level
    20.0 10028395 - Musculoskeletal and connective tissue disorders 10049088 Osteopenia PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2011-002132-10 Sponsor Protocol Number: MO27775 Start Date*: 2012-03-08
    Sponsor Name:F. Hoffmann-La Roche Ltd.
    Full Title: A randomized, two-arm, open-label, multicenter Phase II trial assessing the efficacy and safety of pertuzumab given in combination with trastuzumab plus an aromatase inhibitor in first line patien...
    Medical condition: HER2- and hormone receptor-positive advanced (metastatic or locally advanced) breast cancer
    Disease: Version SOC Term Classification Code Term Level
    14.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10065430 HER-2 positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: FR (Completed) ES (Completed) GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2014-004517-84 Sponsor Protocol Number: ITFE-2026-C10 Start Date*: 2015-02-26
    Sponsor Name:ITF Research Pharma S.L.U
    Full Title: A PHASE II PROSPECTIVE, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED AND MULTI-CENTRE CLINICAL TRIAL TO ASSESS THE SAFETY OF 0.005 % ESTRIOL VAGINAL GEL IN HORMONE RECEPTOR-POSITIVE POSTMENOPAUSAL ...
    Medical condition: In postmenopausal hormone receptor positive breast cancer, treatment with aromatase inhibitors is the most effective and well-studied therapy. Lack of adherence is common due to the side-effects; v...
    Disease:
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) SE (Completed)
    Trial results: View results
    EudraCT Number: 2007-005752-16 Sponsor Protocol Number: CR0207-22 Start Date*: 2008-03-03
    Sponsor Name:Cancer Research UK
    Full Title: A Cancer Research UK randomised phase II trial of ATN-224 (copper binding agent) in combination with exemestane versus exemestane alone in post-menopausal women with recurrent or advanced, oestroge...
    Medical condition: recurrent or advanced oestrogen and/or progesterone receptor positive breast cancer
    Disease: Version SOC Term Classification Code Term Level
    9.1 10006198 Breast cancer recurrent LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2019-000510-11 Sponsor Protocol Number: Hermione-7 Start Date*: 2019-10-31
    Sponsor Name:UNIVERSITÀ DEGLI STUDI MILANO BICOCCA
    Full Title: A Phase 2, open label, multicenter, single arm trial evaluating the activity and safety of Abemaciclib + Aromatase Inhibitors (AIs) after 1st-line treatment with High-Dose Fulvestrant in Hormone-Re...
    Medical condition: Advanced breast cancer Hormone-Receptor-Positive (HR+), Human-Epidermal-Growth-factor-negative (HER2-)
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10006283 Breast neoplasm malignant female LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    EudraCT Number: 2004-000727-15 Sponsor Protocol Number: 9238IL/0048 Start Date*: 2004-12-03
    Sponsor Name:AstraZeneca AB
    Full Title: A Randomized, Double Blind, Multicenter Study to Compare the Efficacy and Tolerability of Fulvestrant (FASLODEX™) vs. Exemestane (AROMASIN™) in Postmenopausal Women with Hormone Receptor Positive A...
    Medical condition: Hormone receptor positive breast cancer with disease progression after prior non-steroidal aromatase inhibitor (AI) therapy
    Disease:
    Population Age: Elderly Gender: Female
    Trial protocol: HU (Completed)
    Trial results: View results
    EudraCT Number: 2014-005126-35 Sponsor Protocol Number: GBG86-DESIREE Start Date*: 2015-06-03
    Sponsor Name:GBG Forschungs GmbH
    Full Title: A multicenter, randomized, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer
    Medical condition: Advance Breast cancer under endocrine treatment
    Disease: Version SOC Term Classification Code Term Level
    21.1 100000004864 10072737 Advanced breast cancer LLT
    21.1 100000004864 10072740 Locally advanced breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2013-003170-27 Sponsor Protocol Number: GEICAM/2013-02 Start Date*: 2013-11-21
    Sponsor Name:GEICAM (Fundación Grupo Español de Investigación en Cáncer de Mama)
    Full Title: Phase III study of Palbociclib (PD-0332991) in combination with Exemestane versus chemotherapy (capecitabine) in Hormonal Receptor (HR) positive/HER2 negative Metastatic Breast Cancer (MBC) patient...
    Medical condition: Patients with hormonal receptor positive and HER2 negative MBC who are resistant to prior NSAI therapy.
    Disease: Version SOC Term Classification Code Term Level
    16.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: ES (Completed) AT (Completed) HU (Completed) LV (Completed) IE (Completed)
    Trial results: View results
    EudraCT Number: 2015-000106-19 Sponsor Protocol Number: GO29689 Start Date*: 2015-12-10
    Sponsor Name:Genentech, Inc
    Full Title: A PHASE II, OPEN-LABEL, RANDOMIZED STUDY OF GDC-0810 VERSUS FULVESTRANT IN POSTMENOPAUSAL WOMEN WITH ADVANCED OR METASTATIC ER+/HER2- BREAST CANCER RESISTANT TO AROMATASE INHIBITOR THERAPY
    Medical condition: Advanced or Metastatic ER+/HER2- Breast Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10070575 Estrogen receptor positive breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: DE (Completed) ES (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-003510-13 Sponsor Protocol Number: IRST174.08 Start Date*: 2013-05-07
    Sponsor Name:IRCCS ISTITUTO SCIENTIFICO ROMAGNOLO PER LO STUDIO E LA CURA DEI TUMORI
    Full Title: A phase II non randomized study evaluating the role of Androgen Receptors as Targets for therapy of pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/A...
    Medical condition: pre-treated post-menopausal patients with ER/PgR-negative/AR-positive or ER and/or PgR-positive/AR-positive metastatic breast cancer
    Disease: Version SOC Term Classification Code Term Level
    15.1 100000004864 10027475 Metastatic breast cancer LLT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: IT (Prematurely Ended)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 19:28:43 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA